Biogen | BIIB - Selling And Administration Expenses


Biogen reported $545.2M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Bayer EUR 4.05B 647M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 128M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Teva Pharmaceutical Industries USD 1.12B 147M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025